Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Actinic Keratosis (AK) Clear all
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

NCT04319159
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis

NCT01516515
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Vehicle gel, SR-T100 with 2.3% of SM
Drug
Lead sponsor
G&E Herbal Biotechnology Co., LTD
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Rancho Mirage, California • Longmont, Colorado • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Jun 25, 2026, 8:01 AM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

NCT07144345
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

NCT02866695
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ingenol mebutate gel 0.015%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)

NCT01458587
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid PDT (ALA), Vehicle PDT (VEH)
Drug
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Orange Park, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

NCT01475955
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation, Spot ALA 2 hour incubation, Vehicle PDT, Blue Light Treatment
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 1 Interventional

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate 0.015%
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

NCT02251652
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Ingenol Mebutate, Cryotherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Jun 25, 2026, 8:01 AM EDT
Recruiting Early Phase 1 Interventional

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

NCT07286318
View directory record Official record
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
Interventions
Topical niacinamide 5% cream, Sunscreen
Drug
Lead sponsor
Marissa Lobl
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 25, 2026, 8:01 AM EDT
Completed No phase listed Observational Results available

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

NCT05260073
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Tirbanibulin
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jun 25, 2026, 8:01 AM EDT
Completed No phase listed Observational

A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

NCT00989313
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Lesion count
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Jun 25, 2026, 8:01 AM EDT
Not listed Phase 4 Interventional

Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses

NCT01229319
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Drug
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 1 Interventional

Treatment of Actinic Keratoses (AK) on the Face

NCT02411851
View directory record Official record
Conditions
Actinic Keratoses
Interventions
ingenol mebutate 0.015%, dermasil lotion
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 2 Interventional

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

NCT00335179
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aldara (imiquimod 5% cream), Vehicle cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

NCT03116698
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily, Placebo twice daily
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Cerritos, California • Fremont, California • Palm Springs, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jun 25, 2026, 8:01 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

NCT05662202
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 8:01 AM EDT
Terminated Phase 2 Interventional

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

NCT00865878
View directory record Official record
Conditions
Actinic Keratoses, Skin Neoplasms
Interventions
Aminolevulinic Acid, Vehicle
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 3 Interventional

Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses

NCT02124733
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic acid based photodynamic therapy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

NCT03210740
View directory record Official record
Conditions
Actinic Keratosis
Interventions
AM001 Cream, 7.5%, Vehicle Cream
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

NCT00115154
View directory record Official record
Conditions
Keratosis
Interventions
Aldara (imiquimod) cream, 5%
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
18
States / cities
Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2007 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 2 Interventional

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions
eflornithine, triamcinolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jun 25, 2026, 8:01 AM EDT
Withdrawn Not applicable Interventional

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

NCT00814528
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-ALA plus Blu-Light, 5-FU, Imiquimod or treatment with cryotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jun 25, 2026, 8:01 AM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

NCT07144852
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 25, 2026, 8:01 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Jun 25, 2026, 8:01 AM EDT